METHOD OF DIAGNOSING REGRESSION OF BREAST CANCER AFTER NEOADJUVANT DRUG THERAPY Russian patent published in 2023 - IPC A61B5/05 A61B10/04 G01N33/574 

FIELD: medicine; pathological anatomy; oncology.

SUBSTANCE: invention can be used for diagnosing regression of breast cancer (BC) after neoadjuvant drug therapy. An X-ray examination of the tumor tissue is performed. The dimensions of the largest cross-sectional plane area of the X-ray positive bed are assessed. Serial sections are made for histological preparations with simultaneous digital mapping of the bed and marking with histological dyes. The percentage of carcinoma in situ, the number of lymph nodes with metastases, and the size of the largest metastasis are determined. The tumor regression index is calculated using the following formula: ,, where d₁, d₂ are the microscopic dimensions of the tumor bed, d_by is the largest area of the cross-sectional plane of the X-ray positive bed of the primary tumor. is the severity of the invasive component, calculated based on the percentage of carcinoma in situ (CIS) of invasive cancer (CA) in the tumor, LN is the number of lymph nodes with metastases, d_met is the largest diameter of the metastasis in the lymph node. The result of the calculations is the tumor regression class, ranked from I to III: I is minimal residual tumor with index less than 1.36; II is moderate residual tumor with index 1.37–3.28; III is pronounced residual tumor with index 3.29 or more.

EFFECT: invention improves the accuracy of determining the quantitative and qualitative indicators of the tumor bed required to assess the degree of pathological regression of breast cancer in response to treatment.

1 cl, 6 ex, 4 dwg